Table 3.

Cox regression analysis of the association between the characteristics and outcomes in patients with HCM

Variants	Unadjusted HR (95% CI)	Unadjusted P-value	Adjusted HR (95% CI)	Adjusted P-value
Primary endpoint
MACEs
Per 1 increase in the maximal T/C ratio	1.250 (1.109–1.410)	< 0.001	1.214 (1.059–1.391)	0.005
Secondary endpoints
HF
Per 1 increase in the maximal T/C ratio	1.308 (1.096–1.562)	0.003	1.372 (1.094–1.722)	0.006
Thromboembolic events
Per 1 increase in the maximal T/C ratio	1.322 (1.083–1.612)	0.006	1.242 (1.019–1.514)	0.032
Ventricular arrhythmias
Per 1 increase in the maximal T/C ratio	1.275 (1.089–1.493)	0.002	1.240 (1.003–1.533)	0.047

Models were adjusted for age, sex, New York Heart Association functional class, syncope, atrial fibrillation, non-sustained ventricular tachycardia, coronary artery disease, valvular heart disease, carotid artery disease, chronic kidney disease, history of stroke, family history of sudden cardiac death, treatment strategies (septal reduction therapy or medical therapy alone), maximal left ventricular (LV) wall thickness, left ventricular ejection fraction, left atrial diameter, LV end-diastolic diameter, LV end-diastolic volume index, LV outflow tract gradient, LV apical aneurysm and late gadolinium enhancement extent

CI confidential interval, HCM hypertrophic cardiomyopathy, HF heart failure, HR hazard ratio, MACEs major adverse cardiovascular events, T/C trabeculation to compaction